Related Experiment Videos
Precursor frequency analysis of bryostatin activated lymphocytes
M D Fleming1, S K Barrett, H D Bear
1Department of Surgery, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
The Journal of Surgical Research
|July 1, 1994
Summary
Bryostatin 1 and ionomycin activate T cells, demonstrating potent antigen-specific antitumor effects. This suggests the combination preferentially activates pre-sensitized T cells, offering a novel immunotherapy approach.
Area of Science:
- Immunology
- Cancer Research
- Cell Biology
Background:
- Bryostatin 1 (Bryo) is a protein kinase C activator.
- T cells stimulated with Bryo and ionomycin (Io) rapidly expand in low-dose IL-2.
- Bryo/Io-activated T cells from tumor-draining lymph nodes exhibit significant antigen-specific antitumor efficacy in vivo.
Purpose of the Study:
- To investigate the hypothesis that Bryo/Io preferentially activates antigen-sensitized T cells.
- To determine if Bryo/Io treatment enriches for antigen-specific T cells.
- To evaluate the role of T cell or CD8+ cell enrichment in the observed expansion.
Main Methods:
- Utilized an allogeneic response model in C57BL/6 and DBA/2 mice.
- Determined cytolytic T lymphocyte (CTL) precursor frequency (PF) using limiting dilution analysis (LDA) before and after Bryo/Io treatment and expansion.
- Analyzed PF in T lymphocytes and CD8+ T cells isolated from primed splenocytes.
Main Results:
- Bryo/Io treatment did not induce non-specific cytolysis.
- The increase in PF after Bryo/Io expansion was not solely due to T cell or CD8+ cell enrichment.
- Data indicated preferential activation and expansion of antigen-sensitized T cells.
Conclusions:
- The Bryo/Io combination therapy preferentially activates antigen-sensitized T cells.
- This selective activation contributes to the observed antigen-specific antitumor efficacy.
- Findings support the potential of Bryo/Io as a targeted immunotherapy strategy.